PROBLEM TO BE SOLVED: To provide a new crystal of 2-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-benzimidazole-5-yl]-1,3- benzoxazole having excellent storage stability capable of maintaining the same quality, when being stored as a pharmaceutical technical product of a therapeutic agent for a neurodegenerative disease or the like and to provide a production method thereof.SOLUTION: There is provided a crystal of 2-[2-methyl-1-(tetrahydro-2H-piran-4-il)-1H-benzimidazole-5-il]-1,3- benzoxazole in which, in a powder X-ray diffraction spectrum, a diffraction angle (2θ) shows main peaks at 11.6°, 15.9°, 17.4° and 22.1°(±0.2° respectively). A production method thereof is also provided.SELECTED DRAWING: NoneCOPYRIGHT: (C)2016,JPO&INPIT【課題】神経変性疾患等の治療薬の医薬原体として保存する際に同一品質が維持できる優れた保存安定性を有する2-[2-メチル-1-(テトラヒドロ-2H-ピラン-4-イル)-1H-ベンズイミダゾール-5-イル]-1,3-ベンズオキサゾールの新規結晶及びその製造方法の提供。【解決手段】粉末X線回折スペクトルにおいて、回折角(2θ)が 11.6°、15.9°、17.4°、および22.1°(それぞれ±0.2°)に主ピークを示す、2-[2-メチル-1-(テトラヒドロ-2H-ピラン-4-イル)-1H-ベンズイミダゾール-5-イル]-1,3-ベンズオキサゾールの結晶および当該結晶の製造方法。【選択図】なし
